Abstract:Human cytochrome P450 3A4 (hCYP3A4), one of the most important drug-metabolizing enzymes, catalyze the metabolic clearance of ∼50% therapeutic drugs. CYP3A4 inhibitors have been used for improving the in vivo efficacy of hCYP3A4-substrate drugs. However, most of existing hCYP3A4 inhibitors may trigger serious adverse effects or undesirable effects on endogenous metabolism. This study aimed to discover potent and orally active hCYP3A4 inhibitors from chalcone derivatives and to test their anti-hCYP3A4 effects both in vitro and in vivo. Following three rounds of screening and structural optimization, the isoquinoline chalcones were found with excellently anti-hCYP3A4 effects. SAR studies showed that introducing an isoquinoline ring on the A-ring significantly enhanced anti-CYP3A4 effect, generating A10 (IC50 = 102.10 nM) as a promising lead compound. The 2nd round of SAR studies showed that introducing a substituent group at the para position of the carbonyl group on B-ring strongly improved the anti-CYP3A4 effect. As a result, C6 was identified as the most potent hCYP3A4 inhibitor (IC50 = 43.93 nM) in human liver microsomes (HLMs). C6 also displayed potent anti-hCYP3A4 effect in living cells (IC50 = 153.00 nM), which was superior to the positive inhibitor ketoconazole (IC50 = 251.00 nM). Mechanistic studies revealed that C6 could potently inhibit CYP3A4-catalyzed N-ethyl-1,8-naphthalimide (NEN) hydroxylation in a competitive manner (Ki = 30.00 nM). Moreover, C6 exhibited suitable metabolic stability in HLMs and showed good safety profiles in mice. In vivo tests demonstrated that C6 (100 mg/kg, orally administration) significantly increased the AUC(0-inf) of midazolam by 3.63-fold, and strongly prolonged its half-life by 1.66-fold compared with the vehicle group in mice. Collectively, our findings revealed the SARs of chalcone derivatives as hCYP3A4 inhibitors and offered several potent chalcone-type hCYP3A4 inhibitors, while C6 could serve as a good lead compound for developing novel, orally active CYP3A4 inhibitors with improved druglikeness properties.

Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations.

Computational and in Vitro Studies on the Inhibitory Effects of Herbal Compounds on Human Cytochrome P450 1A2

Inhibition of Chrysin on Xanthine Oxidase Activity and Its Inhibition Mechanism.

Exploring the structure characteristics and major channels of cytochrome P450 2A6, 2A13, and 2E1 with pilocarpine.

Computational studies of the binding mechanism of calmodulin with chrysin.

Synthesis, Characterization and Xanthine Oxidase Inhibition of Cu(Ii)-Chrysin Complex

Novel Natural Inhibitors Of Cyp1a2 Identified By In Silico And In Vitro Screening

Chrysin attenuates inflammation by regulating M1/M2 status via activating PPARγ.

Metabolic kinetics of tanshinone Ⅱ A in rat liver microsomal enzyme

Design, Synthesis, and Biological Evaluation of Chrysin Derivatives As Potential FabH Inhibitors.

Computational Insights into the Different Catalytic Activities of CYP3A4 and CYP3A5 Toward Schisantherin E.

Probe substrates assay estimates the effect of polyphyllin H on the activity of cytochrome P450 enzymes in human liver microsomes

Design, Synthesis and Biological Evaluation of Chalcone Derivatives As Potent and Orally Active Hcyp3a4 Inhibitors.

Synthesis of Chrysin Derivatives and Screening of Antitumor Activity

Investigation of binding features: effects on the interaction between CYP2A6 and inhibitors.

Discovery and Characterization of Novel, Potent, and Selective Cytochrome P450 2j2 Inhibitors

Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression

Investigation of the interaction between Chrysoeriol and xanthine oxidase using computational and in vitro approaches

Molecular dynamics simulations of CYP2E1.

Investigation of Ligand Selectivity in CYP3A7 by Molecular Dynamics Simulations

Design, Synthesis and Biological Evaluation of Chrysin Long-Chain Derivatives As Potential Anticancer Agents